INDBInternet News Database 2.5 Updated 1 min ago · 306 sources Show or hide images Light or dark

Next-Generation Oral SERD Approved for Breast Cancer

Save Like Comments Compare coverage
Image from Medpagetoday

Summary

(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated...

Description from Medpagetoday.

Who is covering this

  1. Medpagetoday Center Factuality: Mostly factual US
    Next-Generation Oral SERD Approved for Breast Cancer

    (MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated...

Comments

Comments need JavaScript.